Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
0.04
P/B Ratio
0.76
Industry P/E
--
Debt to Equity
0
ROE
-5.35 %
ROCE
-378.24 %
Div. Yield
0 %
Book Value
1.63
EPS
--
CFO
$-79.21 Mln
EBITDA
$-98.74 Mln
Net Profit
$-84.63 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| -60.50 | -41.91 | -56.11 | 367.73 | -57.97 | -62.42 | -- |
|
BSE Sensex*
| -5.65 | -3.07 | -9.18 | 0.22 | 9.95 | 17.63 | 9.82 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| 1,116.98 | -86.12 | -84.74 | -38.02 | 77.78 | 48.85 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.65 | 10,257.64 | 20.82 | 23.13 | |
| 34.62 | 13,507.42 | -- | -28.77 | |
| 110.75 | 11,042.16 | 33.66 | 14.16 | |
| 97.19 | 9,680.89 | 42.64 | 19.71 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for... the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 Read more
CEO & Director
Dr. Alexandra MacLean M.D.
CEO & Director
Dr. Alexandra MacLean M.D.
Headquarters
Bay Harbor Islands, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Avenue Therapeutics Inc (ATXI) stood at $ 4 Mln as on 30-Sep-24
The share price of Avenue Therapeutics Inc (ATXI) is $0.79 (NASDAQ) as of 14-Mar-2025 16:00 EDT. Avenue Therapeutics Inc (ATXI) has given a return of -57.97% in the last 3 years.
Avenue Therapeutics Inc (ATXI) has a market capitalisation of $ 2 Mln as on 13-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Avenue Therapeutics Inc (ATXI) is 0.76 times as on 13-Mar-2025, a 72% discount to its peers’ median range of 2.71 times.
The P/E ratio of Avenue Therapeutics Inc (ATXI) is 0.04 times as on 13-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Avenue Therapeutics Inc (ATXI) and enter the required number of quantities and click on buy to purchase the shares of Avenue Therapeutics Inc (ATXI).
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
The CEO & director of Dr. Alexandra MacLean M.D.. is Avenue Therapeutics Inc (ATXI), and CFO & Sr. VP is Dr. Alexandra MacLean M.D..
There is no promoter pledging in Avenue Therapeutics Inc (ATXI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Avenue Therapeutics Inc. (ATXI) | Ratios |
|---|---|
|
Return on equity(%)
|
-510.83
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Avenue Therapeutics Inc (ATXI) was $0 Mln.
$0.02
(
